Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients-Reference-Cited by-同舟云学术

Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients

Published:2023-04-18 Issue: Volume:18 Page:
ISSN:1758-3764
Container-title:European Cardiology Review
language:en
Short-container-title:Eur Cardiol

Author:

Komiyama Maki¹^ORCID,Dan Gheorghe-Andrei²^ORCID,Hasegawa Koji¹

Affiliation:

1. Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

2. Carol Davila University of Medicine and Pharmacy, Colentina University Hospital, Bucharest, Romania

Abstract

Antiplatelet agents are routinely used to treat patients with chronic atherosclerotic coronary artery disease. Treatment with the addition of a low dose of rivaroxaban as dual-pathway inhibition (DPI) decreases ischaemic events at the expense of increased bleeding. At present, the balance between thrombotic and bleeding risks must be carefully weighed up when considering DPI. However, with the introduction of activated coagulation factor XI inhibitors, which have fewer bleeding effects, the use of DPI in patients with atherosclerotic cardiovascular diseases could be extended.

Publisher

Radcliffe Media Media Ltd

Subject

Cardiology and Cardiovascular Medicine

Reference9 articles.

1. Yasuda S, Kakita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;381:1103–13. https://doi.org/10.1056/NEJMoa1904143; PMID: 31475793.

2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289–367. https://doi.org/10.1093/eurheartj/ehaa575; PMID: 32860058.

3. Arbelo E, Dagres N. The 2020 ESC atrial fibrillation guidelines for atrial fibrillation catheter ablation, CABANA, and EAST. Europace 2022;24:ii3–7. https://doi.org/10.1093/europace/euab332; PMID: 35661865.

4. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19. https://doi.org/10.1056/NEJMoa1112277; PMID: 22077192.

5. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319–30. https://doi.org/10.1056/NEJMoa1709118; PMID: 28844192.